Neuroleptic malignant syndrome, a rare but potentially fatal side effect
of antipsychotic medications, has often proven refractory to conventional
antiparkinsonian medications. The authors report a dramatic response of
this syndrome to the dopamine agonist bromocriptine mesylate in a patient
receiving fluphenazine decanoate.Abstract Teaser